| Date | Time | Source | Headline | Symbol | Company |
| 03/13/2024 | 3:00AM | RNS Regulatory News | MaxCyte, Inc. Reports Q4 & FY 2023 Financial Results | LSE:MXCT | Maxcyte Inc |
| 03/12/2024 | 4:05PM | UK Regulatory | MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance | LSE:MXCT | Maxcyte Inc |
| 03/06/2024 | 3:58AM | RNS Regulatory News | MaxCyte, Inc. TR-1: Notification of major holdings | LSE:MXCT | Maxcyte Inc |
| 03/05/2024 | 3:43PM | Alliance News |  EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit | LSE:MXCT | Maxcyte Inc |
| 03/05/2024 | 2:00AM | RNS Regulatory News | MaxCyte, Inc. Preliminary FY Results & 2024 Guidance | LSE:MXCT | Maxcyte Inc |
| 03/04/2024 | 4:05PM | UK Regulatory | MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results | LSE:MXCT | Maxcyte Inc |
| 03/01/2024 | 12:57PM | RNS Regulatory News | MaxCyte, Inc. Total Voting Rights | LSE:MXCT | Maxcyte Inc |
| 02/29/2024 | 4:21AM | RNS Regulatory News | MaxCyte, Inc. Exercise of options and PDMR dealing | LSE:MXCT | Maxcyte Inc |
| 02/26/2024 | 2:00AM | RNS Regulatory News | MaxCyte, Inc. TR-1: Notification of major holdings | LSE:MXCT | Maxcyte Inc |
| 02/09/2024 | 8:05AM | RNS Regulatory News | MaxCyte, Inc. Notice of Results | LSE:MXCT | Maxcyte Inc |
| 02/09/2024 | 8:05AM | UK Regulatory | MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences | LSE:MXCT | Maxcyte Inc |
| 02/01/2024 | 4:24AM | RNS Regulatory News | MaxCyte, Inc. Total Voting Rights | LSE:MXCT | Maxcyte Inc |
| 01/31/2024 | 2:00AM | RNS Regulatory News | MaxCyte, Inc. Director/PDMR Shareholding | LSE:MXCT | Maxcyte Inc |
| 01/30/2024 | 9:29AM | RNS Regulatory News | MaxCyte, Inc. Holding(s) in Company | LSE:MXCT | Maxcyte Inc |
| 01/30/2024 | 8:58AM | Alliance News | IN BRIEF: MaxCyte signs licencing deal with cell therapy company Wugen | LSE:MXCT | Maxcyte Inc |
| 01/30/2024 | 8:05AM | UK Regulatory | MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers | LSE:MXCT | Maxcyte Inc |
| 01/30/2024 | 8:05AM | RNS Regulatory News | MaxCyte, Inc. Signing of Strategic Platform License | LSE:MXCT | Maxcyte Inc |
| 01/29/2024 | 12:56PM | Alliance News | IN BRIEF: MaxCyte chief scientific officer leaves firm | LSE:MXCT | Maxcyte Inc |
| 01/29/2024 | 11:52AM | RNS Regulatory News | MaxCyte, Inc. TR-1: Notification of major holdings | LSE:MXCT | Maxcyte Inc |
| 01/29/2024 | 2:00AM | RNS Regulatory News | MaxCyte, Inc. Filing of Form 8-K | LSE:MXCT | Maxcyte Inc |
| 01/23/2024 | 1:39PM | Alliance News | TRADING UPDATES: Esken's Southend Airport faces further allegations | LSE:MXCT | Maxcyte Inc |
| 01/23/2024 | 8:05AM | UK Regulatory | MaxCyte, Inc. Signing of Strategic Platform License | LSE:MXCT | Maxcyte Inc |
| 01/09/2024 | 7:18AM | Alliance News | MaxCyte's strategic platform licences redeem otherwise modest results | LSE:MXCT | Maxcyte Inc |
| 01/09/2024 | 2:00AM | UK Regulatory | MaxCyte, Inc. Preliminary Unaudited Q4 and FY 2023 Results | LSE:MXCT | Maxcyte Inc |
| 01/05/2024 | 2:00AM | UK Regulatory | MaxCyte, Inc. Grant of Options and PDMR Dealing | LSE:MXCT | Maxcyte Inc |
| 01/03/2024 | 9:04AM | Alliance News | MaxCyte teams with Singapore-based Lion to support TCR-T cell work | LSE:MXCT | Maxcyte Inc |
| 01/03/2024 | 8:05AM | UK Regulatory | MaxCyte, Inc. Signing of Strategic Platform License | LSE:MXCT | Maxcyte Inc |
| 01/02/2024 | 4:23AM | UK Regulatory | MaxCyte, Inc. Total Voting Rights | LSE:MXCT | Maxcyte Inc |
| 01/02/2024 | 2:00AM | UK Regulatory | MaxCyte, Inc. Confirmation of Board change | LSE:MXCT | Maxcyte Inc |
| 12/29/2023 | 2:00AM | UK Regulatory | MaxCyte, Inc. Exercise of options and PDMR dealing | LSE:MXCT | Maxcyte Inc |